Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors

Some individuals with non-small-cell lung cancer (NSCLC) benefit from therapies targeting epidermal growth factor receptor (EGFR), and the characterization of a new mechanism of resistance to the EGFR-specific antibody gefitinib will provide valuable insight into how therapeutic strategies might be...

Descripción completa

Detalles Bibliográficos
Autores principales: C., George Priya Doss, B., Rajith, Chakraborty, Chiranjib, N., NagaSundaram, Ali, Shabana Kouser, Zhu, Hailong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121614/
https://www.ncbi.nlm.nih.gov/pubmed/25091415
http://dx.doi.org/10.1038/srep05868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121614/
https://www.ncbi.nlm.nih.gov/pubmed/25091415
http://dx.doi.org/10.1038/srep05868

Ejemplares similares